Nabla Bio and Takeda Expand Partnership to Advance AI-Driven Protein Therapeutics

Published: 15 Oct 2025

Author: Precedence Research

Share :

Nabla Bio, a leading biotech firm aiming to develop de novo therapeutics design with generative AI, has announced its strategic collaboration with Takeda for a multiyear research program. According to the agreement signed between these two firms, Nabla Bio will receive double-digit millions in upfront and research cost payments. It will be eligible to receive success-based payments. The value of this payment may exceed $1 billion in total.

It's a second collaboration that will deploy a proprietary biomolecular design platform by Nabla Bio and Joint Atomic Model — JAM across an early-stage development program by Takeda. This new collaboration will fully commit to designing a de novo platform, but it is not limited to this project alone. They are working in parallel on various targets, including multiple specific and challenging ones, along with other custom therapies.

Surge Biswas, Ph.D., Chief Executive Officer and Co-founder of Nabla Bio. Mentioned about their perspective on this collaboration, "Since 2022, we’ve collaborated with Takeda to push the boundaries of next-generation biologics discovery, This second collaboration builds on the success of our first program and reflects our shared conviction that de novo design and AI-driven optimization, powered by foundation models like JAM, can unlock entirely new therapeutic spaces and accelerate the development of new medicines at a scale and speed not seen before."

According to the people working at Takeda, they are building innovative methods to accelerate drug development more reliably and quickly by using AI advancements. By acknowledging the success of their first collaboration, they have decided to collaborate again, applying cutting-edge AI technology and wet labs to design and optimize protein therapeutics for applications across Takeda's therapeutic areas.

Nabla Bio was founded based on the integration of generative AI and human-attached in vitro and in vivo testing. Their AI-designed therapeutics have demonstrated an excellent success rate in pre-clinical properties such as function, pharmacodynamics, and low immunogenicity among non-human primates, highlighting their effective treatment approach using generative AI capabilities.